Ronald van Vollenhoven

71.0k total citations · 13 hit papers
512 papers, 27.7k citations indexed

About

Ronald van Vollenhoven is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Ronald van Vollenhoven has authored 512 papers receiving a total of 27.7k indexed citations (citations by other indexed papers that have themselves been cited), including 448 papers in Rheumatology, 140 papers in Immunology and 127 papers in Genetics. Recurrent topics in Ronald van Vollenhoven's work include Rheumatoid Arthritis Research and Therapies (308 papers), Systemic Lupus Erythematosus Research (247 papers) and Chronic Lymphocytic Leukemia Research (125 papers). Ronald van Vollenhoven is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (308 papers), Systemic Lupus Erythematosus Research (247 papers) and Chronic Lymphocytic Leukemia Research (125 papers). Ronald van Vollenhoven collaborates with scholars based in Sweden, United States and Netherlands. Ronald van Vollenhoven's co-authors include Paul Emery, Roy Fleischmann, Karel Pavelká, Lars Klareskog, Edward Keystone, Désirée van der Heijde, Stanley Cohen, Gerd R Burmester, Robert Landewé and James L. McGuire and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Ronald van Vollenhoven

484 papers receiving 26.8k citations

Hit Papers

The PREMIER study: A multicenter, randomized, double‐blin... 2005 2026 2012 2019 2005 2011 2008 2016 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    2005 1.4k citations Karel Pavelká, Ronald van Vollenhoven et al. Arthritis & Rheumatism profile →
  2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    2011 1.1k citations Richard Furie, Andreas Schwarting et al. Arthritis & Rheumatism profile →
  3. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    2008 866 citations Paul Emery, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases profile →
  4. Systemic lupus erythematosus
    2016 849 citations Murray B. Urowitz, Ronald van Vollenhoven et al. profile →
  5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
    2006 783 citations Paul Emery, Roy Fleischmann et al. Arthritis & Rheumatism profile →
  6. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
    2012 739 citations Ronald van Vollenhoven, Roy Fleischmann et al. profile →
  7. Tofacitinib versus Methotrexate in Rheumatoid Arthritis
    2014 598 citations Roy Fleischmann, Ronald van Vollenhoven et al. profile →
  8. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    2013 502 citations Cem Gabay, Paul Emery et al. The Lancet profile →
  9. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Désirée van der Heijde, Robert Landewé et al. Arthritis & Rheumatism profile →
  10. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
    2020 195 citations Désirée van der Heijde, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases profile →
  11. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
    2020 180 citations Ronald van Vollenhoven, Gerd R Burmester et al. Annals of the Rheumatic Diseases profile →
  12. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
    2022 139 citations Eric F. Morand, Marilyn C. Pike et al. Arthritis & Rheumatology profile →
  13. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    2023 79 citations Eric F. Morand, Ronald van Vollenhoven et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronald van Vollenhoven Sweden 80 20.6k 10.0k 6.8k 4.8k 4.4k 512 27.7k
Mark C. Genovese United States 76 14.1k 0.7× 8.5k 0.9× 6.5k 1.0× 2.9k 0.6× 3.5k 0.8× 317 22.7k
Josef S Smolen Austria 89 25.5k 1.2× 10.1k 1.0× 9.6k 1.4× 3.6k 0.8× 4.0k 0.9× 509 35.4k
Edward Keystone Canada 69 17.0k 0.8× 6.8k 0.7× 7.8k 1.2× 2.8k 0.6× 4.2k 0.9× 404 24.5k
Roy Fleischmann United States 69 16.7k 0.8× 6.4k 0.6× 8.1k 1.2× 2.2k 0.5× 3.9k 0.9× 347 22.9k
Ferdinand C. Breedveld Netherlands 67 15.2k 0.7× 5.4k 0.5× 5.4k 0.8× 3.4k 0.7× 2.6k 0.6× 182 21.9k
Joel M. Kremer United States 77 15.2k 0.7× 5.0k 0.5× 6.9k 1.0× 1.8k 0.4× 4.1k 0.9× 322 23.2k
Yoshiya Tanaka Japan 80 14.5k 0.7× 9.6k 1.0× 5.2k 0.8× 3.0k 0.6× 3.8k 0.9× 1.1k 30.4k
Ben A. C. Dijkmans Netherlands 83 18.3k 0.9× 6.3k 0.6× 6.1k 0.9× 2.4k 0.5× 2.1k 0.5× 332 25.0k
Vibeke Strand United States 73 15.4k 0.7× 6.3k 0.6× 5.6k 0.8× 2.2k 0.5× 2.0k 0.5× 522 22.9k
Munther A. Khamashta United Kingdom 84 22.6k 1.1× 10.1k 1.0× 8.7k 1.3× 4.1k 0.9× 1.1k 0.3× 411 31.3k

Countries citing papers authored by Ronald van Vollenhoven

Since Specialization
Citations

This map shows the geographic impact of Ronald van Vollenhoven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald van Vollenhoven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald van Vollenhoven more than expected).

Fields of papers citing papers by Ronald van Vollenhoven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald van Vollenhoven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald van Vollenhoven. The network helps show where Ronald van Vollenhoven may publish in the future.

Co-authorship network of co-authors of Ronald van Vollenhoven

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald van Vollenhoven. A scholar is included among the top collaborators of Ronald van Vollenhoven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald van Vollenhoven. Ronald van Vollenhoven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Askanase, Anca, Richard Furie, Maria Dall’Era, et al.. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine. 11(1). e001124–e001124. 4 indexed citations
4.
Vedder, Daisy, Anna Rudin, Dan Nordström, et al.. (2024). Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study. RMD Open. 10(4). e004838–e004838.
5.
Cramer, Steven C., Robert Landewé, Karen I. Maijer, et al.. (2024). The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study. RMD Open. 10(4). e004622–e004622. 1 indexed citations
6.
Morand, Eric F., Ronald van Vollenhoven, Richard Furie, et al.. (2023). OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB. Annals of the Rheumatic Diseases. 82. 33–34. 5 indexed citations
7.
Morand, Eric F., Marilyn C. Pike, Joan T. Merrill, et al.. (2022). Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 75(2). 242–252. 139 indexed citations breakdown →
8.
Bruce, Ian N, Ronald van Vollenhoven, Eric F. Morand, et al.. (2022). Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials. Lara D. Veeken. 62(4). 1526–1534. 20 indexed citations
9.
Lundell, Anna‐Carin, Merete Lund Hetland, Mikkel Østergaard, et al.. (2021). Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research & Therapy. 23(1). 189–189. 7 indexed citations
10.
Hambardzumyan, Karen, Per Marits, Nancy Vivar, et al.. (2019). Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population. Scandinavian Journal of Rheumatology. 48(5). 362–366. 29 indexed citations
11.
12.
13.
Krieckaert, C., Michael T. Nurmohamed, Ronald van Vollenhoven, et al.. (2017). Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Annals of the Rheumatic Diseases. 77(4). 484–487. 53 indexed citations
14.
Vollenhoven, Ronald van, György Nagy, & Paul P. Tak. (2014). Early start and stop of biologics: has the time come?. BMC Medicine. 12(1). 25–25. 20 indexed citations
15.
16.
Mullazehi, Mohammed, Marius C. Wick, Lars Klareskog, Ronald van Vollenhoven, & Johan Rönnelid. (2012). Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Research & Therapy. 14(3). R100–R100. 41 indexed citations
17.
Björkander, Sophia, et al.. (2012). Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus. Cytokine. 59(2). 392–399. 15 indexed citations
18.
Chatzidionysiou, Katerina, E. Lie, Merete Lund Hetland, et al.. (2012). Seropositivity and response to RTX: Data from the CERERRA collaboration. Annals of the Rheumatic Diseases. 71.
19.
Emery, Paul, et al.. (2007). Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Lara D. Veeken. 47(4). 392–398. 66 indexed citations
20.
Askling, Johan, Michael Fored, Lena Brandt, et al.. (2006). TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS).. Arthritis & Rheumatism. 54.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark C. Genovese Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by Roy Fleischmann Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by Joel M. Kremer Breakdown of academic impact, for papers by Yoshiya Tanaka Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Munther A. Khamashta
Rankless by CCL
2026